Is Synthetic Biologics Inc (SYN) a Stock to Watch After Gaining 2.08% This Week?

Friday, August 05, 2022 02:27 PM | InvestorsObserver Analysts

Mentioned in this article

Is Synthetic Biologics Inc (SYN) a Stock to Watch After Gaining 2.08% This Week?

Overall market sentiment has been down on Synthetic Biologics Inc (SYN) stock lately. SYN receives a Bearish rating from InvestorsObserver Stock Sentiment Indicator.

Synthetic Biologics Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on SYN!

See Full SYN Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down. InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend. Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With SYN Stock Today?

Synthetic Biologics Inc (SYN) stock is trading at $1.47 as of 2:20 PM on Friday, Aug 5, a decline of -$0.10, or -6.37% from the previous closing price of $1.57. The stock has traded between $1.38 and $1.50 so far today. Volume today is high. So far 401,063 shares have traded compared to average volume of 299,604 shares. To screen for more stocks like Synthetic Biologics Inc click here.

More About Synthetic Biologics Inc

Synthetic Biologics is a late-stage biotechnology company focused on developing gut microbiome therapeutics. Its portfolio includes SYN-010, which is intended to treat the underlying causes of irritable bowel syndrome with constipation; and SYN-004 (ribaxamase), which aims to defend the gut microbiome from the effects of regularly used intravenous drugs for the prevention of C. difficile infection, antibiotic-associated diarrhea, and the emergence of antibiotic-resistant organisms. The company is also developing monoclonal antibody therapies for the treatment of pertussis and novel discovery stage biotherapeutics for the treatment of phenylketonuria. Click Here to get the full Stock Report for Synthetic Biologics Inc stock.